Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
dasatinib
i
Other names:
BMS 354825, BMS-354825, BMS354825
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(215)
News
Trials
Company:
Generic mfg.
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
sunitinib (139)
ponatinib (98)
lenvatinib (90)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
pexidartinib (6)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
vorolanib (1)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
SKLB-1028 (0)
sorafenib (180)
anlotinib (139)
sunitinib (139)
ponatinib (98)
lenvatinib (90)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
pexidartinib (6)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
vorolanib (1)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
SKLB-1028 (0)
›
Associations
(215)
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
BCR-ABL1 V299L
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
BCR-ABL1 F317I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
No biomarker
Chordoma
No biomarker
Chordoma
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
BCR-ABL1 F317L
Chronic Myeloid Leukemia
BCR-ABL1 F317L
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
dasatinib
Sensitive: A2 - Guideline
dasatinib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.